Molecular Formula | C11H12Cl2N2O |
Molar Mass | 259.13 |
Density | 1.39±0.1 g/cm3(Predicted) |
Melting Point | 126-128° |
Boling Point | 421.5±35.0 °C(Predicted) |
Flash Point | 208.7°C |
Vapor Presure | 6.35E-07mmHg at 25°C |
pKa | 9.80±0.40(Predicted) |
Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
Refractive Index | 1.61 |
Physical and Chemical Properties | Crystallization, melting point 126~128 deg C. Lofexidine Hydrochloride: C11H12(Cl2N2O? HCl. [21498-08-8]. Crystals from ethanol-diethyl ether or 2-propanol, melting point 221-223 °c; There are also melting points 230-232 °c. Very soluble in water or ethanol, slightly soluble in 2-propanol, a few insoluble in ether. Acute toxicity LD50 mice, rats and dogs (mg/kg):74~147 oral; 8~18 intravenous injection. |
Crystal, melting point 126~128 °c.
ethyl (-)-2-hydroxypropionate is chlorinated with sulfuryl chloride and then condensed with 2,6-= chlorophenol to react the resulting compound with ethylenediamine, the reaction product was cyclized under the action of titanium tetrachloride to obtain (-)-lofexidine.
britrmia was developed. It was marketed in 1992. Imidazoline derivatives. The structure and function are similar to that of clonidine. Central open adrenal receptor agonists, reduce peripheral sympathetic nerve activity, inhibit the release of norepinephrine, relaxation of vascular smooth muscle, resulting in a decrease in blood pressure. Used to alleviate or relieve the withdrawal syndrome of opioids.
LDso (mg/kg) in mice, rats and dogs: 74-147 by mouth; 8-18 by intravenous injection.